Company

AIkido Pharma Inc.

Headquarters: New York, NY, United States

Employees: 4

CEO: Mr. Anthony C. Hayes Esq.

NASDAQ: AIKI -2.81%

Market Cap

$19.5 Million

USD as of Feb. 1, 2023

Market Cap History

AIkido Pharma Inc. market capitalization over time

Evolution of AIkido Pharma Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of AIkido Pharma Inc.

Detailed Description

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

AIkido Pharma Inc. has the following listings and related stock indices.


Stock: NASDAQ: AIKI wb_incandescent

Stock: FSX: BP2M wb_incandescent

Details

Headquarters:

One Rockefeller Plaza

11th Floor

New York, NY 10020

United States

Phone: 703 992 9325